Clinical Trial Update: A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 study investigating rociletinib in combination with MPDL3280A in advanced/metastatic EGFR-mutant non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MPDL3280A (atezolizumab)
• rociletinib (rociletinib)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-07-05